Search

Displaying results 131 - 140 of 1237 in total
  1. Indication

    Graves Disease (Basedow's Disease)

    go.drugbank.com/conditions/DBCOND0050972
    Drugs: Methimazole
    Synonyms: Graves´ Disease, Graves' Disease
  2. Drug

    Lerodalcibep

    go.drugbank.com/drugs/DB19071
    ApprovedInvestigational

    [L54738] PCSK9 is a protein that binds to and promotes the degradation of low-density lipoprotein receptors (LDLRs), which are expressed on hepatocytes regulates circulating LDL levels. … [L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia

  3. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446] … address the significant unmet medical need in patients with homozygous familial hypercholesterolemia (HoFH)—an ultra-rare and life-threatening genetic disorder characterized by extremely high levels of low-density

  4. Drug

    Gelatin

    go.drugbank.com/drugs/DB11242
    ApprovedInvestigationalVet approvedWithdrawn

    Gelatin is mainly produced from porcine skin, and cattle hides and bones. … [A32426] Gelatin is generally recognized as safe (GRAS) by the FDA to be a non-hazardous food or food ingredient.

  5. Drug

    Bemiparin

    go.drugbank.com/drugs/DB09258
    ApprovedInvestigationalWithdrawn

    Bemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH). … Like semuloparin, bemiparin is classified as an ultra-LMH because of its low mean molecular mass of 3600 daltons, which is a unique property of this class [A7866].

    Categories: Heparin (Low Molecular Weight)
  6. Drug

    Nipocalimab

    go.drugbank.com/drugs/DB16257
    ApprovedInvestigational

    [L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis.

  7. Target

    Low-density lipoprotein receptor-related protein 2

    go.drugbank.com/bio_entities/BE0000942
    TargetTransporterHumans

    Multiligand endocytic receptor (By similarity). Acts together with CUBN to mediate endocytosis of high-density lipoproteins (By similarity). Mediates receptor-mediated uptake of polybasic drugs such as aprotinin, aminoglycosides and poly...

    Polypeptides: Low-density lipoprotein receptor-related protein 2
  8. Drug

    Racementhol

    go.drugbank.com/drugs/DB14123
    ApprovedInvestigational

    Mixtures: HASOL Anti Hair Loss, Wok Lok Pain Relieving OilProducts: MyoRx Low Dose Pain Relieving, Low Sugar Cherry Flavor Fishermans Friend Menthol Cough Suppressant
  9. Indication

    Calcium loss

    go.drugbank.com/conditions/DBCOND0098865
    Drugs: Calcium carbonate
    Synonyms: Calcium loss
  10. Target

    Low molecular weight phosphotyrosine protein phosphatase

    go.drugbank.com/bio_entities/BE0003786
    TargetHumans

    Acts on tyrosine phosphorylated proteins, low-MW aryl phosphates and natural and synthetic acyl phosphates with differences in substrate specificity between isoform 1 and isoform 2

    Polypeptides: Low molecular weight phosphotyrosine protein phosphataseSynonyms: Low molecular weight cytosolic acid phosphatase